Reply

We thank Ozaras et  al for their thoughtful comments on our article, “The risk of Hepatitis B Reactivation in HBsAg-Negative and Anti-HBc–Positive Patients Receiving Tumor Necrosis Factor Antagonists.” They pointed out that the cohort of hepatitis B surface antigen (HBsAg)-/antibody to hepatitis B core antigen (anti-HBc)+ patients was a heterogeneous group and those who were negative for antibody to hepatitis B surface antigen were at risk of HBV reactivation when they received potent immunosuppressive therapy such as rituximab.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research